Fluzone High-Dose is a vaccine that helps protect against influenza
illness (flu). Fluzone High-Dose vaccine is for people
Fight the flu with
FLUZONE® HIGH-DOSE.
FLUZONE® HIGH-DOSE is FREE for almost everyone.†
$0 for Medicare Part B
$0 for most Medicare Advantage plans
$0 for most private insurance plans
Fight the flu with FLUZONE® HIGH-DOSE.
FLUZONE® HIGH-DOSE is FREE for almost everyone.†
$0 for Medicare Part B
$0 for most Medicare Advantage plans
$0 for most private insurance plans
Find your Sanofi flu shot.
Flu Shot LocatorFLUZONE® HIGH-DOSE—proven to provide superior flu protection. It has 4x the dose versus standard-dose FLUZONE (INFLUENZA VACCINE).
In a clinical study conducted in 2011-2012 and 2012-2013 in approximately 32,000 adults 65+, the trivalent formulation of Fluzone High-Dose proved to be 24% more effective at preventing the flu than standard-dose Fluzone (Influenza Vaccine).
Compared to Fluzone, the most common side effects were slightly more frequent and included pain at the injection site, muscle ache, tiredness, and headache.
The CDC recommends FLUZONE® HIGH-DOSE, a higher-dose flu vaccine, for people 65+.‡
‡FLUZONE®
HIGH-DOSE, FLUBLOK®, or an adjuvanted
quadrivalent vaccine are preferentially recommended by the CDC for
people 65+ over
You can have confidence in the data.
The effectiveness of FLUZONE® HIGH-DOSE (Influenza Vaccine) has been studied for 10 years across a variety of flu-related complications.
At 65+, your risk of flu and
flu-related complications is
significantly increased.
Factors such as lowered immunity and living with chronic health conditions make getting the flu more likely and more dangerous than when you were younger.
FLUZONE® HIGH-DOSE can help reduce your risk of flu and flu-related complications.
See HowFind your Sanofi flu shot.
Demand more from your flu shot.
Schedule your FLUZONE® HIGH-DOSE vaccine today. It’s the #1 used flu vaccine in people 65+.*
*Internal calculations by Sanofi based on IQVIA database of total flu vaccines administered from 7/23-4/24 in people 65+. Not inclusive of all Federal payers. Study details and information maintained by Sanofi.